Zhenling Ma
Impact in
-
- interferon and immune responses
- Immune cells in cancer
-
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
Papers in
- Immunology 12
- interferon and immune responses 5
- Immune cells in cancer 2
-
- Signaling Pathways in Disease 3
- Co-authors
- Wei Liu (13 shared papers)Yaru Wu (8 shared papers)Gaoliang Ouyang (3 shared papers)Zhengjie Huang (3 shared papers)Mimi Chen (2 shared papers)Zhe Wang (2 shared papers)Shanshan Xiong (2 shared papers)Min Zhang (5 shared papers)
In The Last Decade
Zhenling Ma
22 papers receiving 412 citations
Peers
Comparison fields: 5 of 68
- Immunology 115
- Oncology 117
- Cancer Research 49
- Infectious Diseases 57
- Cardiology and Cardiovascular Medicine 44
Countries citing papers authored by Zhenling Ma
This map shows the geographic impact of Zhenling Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenling Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenling Ma more than expected).
Fields of papers citing papers by Zhenling Ma
This network shows the impact of papers produced by Zhenling Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenling Ma. The network helps show where Zhenling Ma may publish in the future.
Co-authors
The 25 scholars most cited alongside Zhenling Ma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 82 | |
| 2 | 2019 | 60 | |
| 3 | 2023 | 41 | |
| 4 | 2021 | 41 | |
| 5 | 2023 | 26 | |
| 6 | 2018 | 18 | |
| 7 | 2022 | 16 | |
| 8 | 2021 | 16 | |
| 9 | 2024 | 14 | |
| 10 | 2022 | 13 | |
| 11 | 2023 | 12 | |
| 12 | 2021 | 12 | |
| 13 | 2020 | 12 | |
| 14 | 2021 | 11 | |
| 15 | 2023 | 9 | |
| 16 | 2022 | 7 | |
| 17 | 2024 | 7 | |
| 18 | 2022 | 5 | |
| 19 | 2022 | 5 | |
| 20 | 2022 | 5 |
About Zhenling Ma
Zhenling Ma is a scholar working on Immunology, Molecular Biology, Oncology, Infectious Diseases and Cancer Research, having authored 23 papers that have together received 414 indexed citations. Recurring topics across this work include interferon and immune responses (5 papers), Cytokine Signaling Pathways and Interactions (4 papers), Chemokine receptors and signaling (3 papers), Signaling Pathways in Disease (3 papers), Ovarian cancer diagnosis and treatment (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Immune cells in cancer (2 papers) and Cancer Mechanisms and Therapy (2 papers). The work is most often cited by research in Immunology (115 citations), Oncology (117 citations), Cancer Research (49 citations), Infectious Diseases (57 citations) and Cardiology and Cardiovascular Medicine (44 citations). Zhenling Ma has collaborated with scholars based in China, Czechia and Hong Kong. Frequent co-authors include Wei Liu, Yaru Wu, Gaoliang Ouyang, Zhengjie Huang, Mimi Chen, Zhe Wang, Shanshan Xiong, Min Zhang, Wenqing Li and Dan Cui. Their work appears in journals such as The Protein Journal, International Journal of Molecular Sciences, Cell Reports, Signal Transduction and Targeted Therapy and Molecular Biology Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.